Usefulness of tissue microarrays for assessment of protein expression, gene copy number and mutational status of EGFR in lung adenocarcinoma.
Specific inhibitors targeting the epidermal growth factor receptor (EGFR) can increase survival rates in certain lung adenocarcinoma patients with mutations in the EGFR gene. Although such EGFR-targeted therapies have been approved for use, there is no general consensus among surgical pathologists on how the EGFR status should be tested in lung adenocarcinoma tissues and whether the results of immunohistochemistry (IHC), fluorescence in situ hybridization (FISH), and mutational analysis by molecular methods correlate. We evaluated the EGFR status in 61 lung adenocarcinomas by IHC (using total and mutant-specific antibodies against EGFR), by FISH analysis on tissue microarrays (TMAs), and by direct sequencing. The results of each method were compared using χ² and κappa statistics. The sensitivity and negative predictive value estimating the presence of abnormal EGFR for each test was calculated. The results show that, with respect to expression patterns and clinicopathological parameters, the total and mutant-specific EGFR detected by immunohistochemistry and FISH analysis on TMAs are valid and are equivalent to conventional methods performed on whole-tissue sections. Abnormal EGFR was detected in 52.4% of patients by IHC, FISH, and sequencing. The best sensitivity (100%) and negative predictive value (100%) was determined by evaluating the EGFR status with all methods. Testing for molecular changes in EGFR using a single test is likely to underestimate the presence of EGFR abnormalities. Taken together, these results demonstrate the high potential of TMAs to test for the major mechanisms of EGFR activation in patients with lung adenocarcinoma.
Ilie
Marius I
MI
Laboratory of Clinical and Experimental Pathology, Louis Pasteur Hospital, 06002 Nice Cedex 01, France.
Hofman
Véronique
V
Bonnetaud
Christelle
C
Havet
Katia
K
Lespinet-Fabre
Virginie
V
Coëlle
Céline
C
Gavric-Tanga
Virginie
V
Vénissac
Nicolas
N
Mouroux
Jerôme
J
Hofman
Paul
P
D000230:Adenocarcinoma / Q000737:chemistry* / Q000235:genetics; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D066246:ErbB Receptors / Q000032:analysis* / Q000235:genetics; D005260:Female; D018628:Gene Dosage; D006801:Humans; D007150:Immunohistochemistry; D017404:In Situ Hybridization, Fluorescence; D008175:Lung Neoplasms / Q000737:chemistry* / Q000235:genetics; D008297:Male; D008875:Middle Aged; D009154:Mutation; D046888:Tissue Array Analysis / Q000379:methods*
D066246:ErbB Receptors
J Clin Oncol. 2005 Apr 10;23(11):2493-501
15710947
J Clin Oncol. 2003 Jul 15;21(14):2787-99
12860957
Mol Cell Proteomics. 2008 Oct;7(10):1902-24
18687633
Int J Cancer. 2001 Oct 1;94(1):1-5
11668471
Mod Pathol. 2009 Jan;22(1):128-33
18997733
Ann Oncol. 2007 Apr;18(4):752-60
17317677
Clin Cancer Res. 2009 May 1;15(9):3023-8
19366827
Clin Cancer Res. 2001 Jul;7(7):1850-5
11448895
Curr Oncol. 2009 Jan;16(1):27-48
19229369
N Engl J Med. 2009 Sep 3;361(10):947-57
19692680
Clin Cancer Res. 2006 Dec 15;12(24):7242-51
17189395
Br J Cancer. 2008 Mar 11;98(5):956-64
18268492
Cancer. 2005 Mar 15;103(6):1265-73
15712203
J Pathol. 2001 Sep;195(1):72-9
11568893
J Mol Diagn. 2010 Mar;12(2):169-76
20093391
Nat Clin Pract Oncol. 2006 Jan;3(1):50-7; quiz 1 p following 57
16407879
J Clin Oncol. 2008 Feb 20;26(6):983-94
18281673
Semin Oncol. 2002 Feb;29(1 Suppl 4):3-14
11894009
Curr Opin Oncol. 2005 Mar;17(2):118-22
15725915
Expert Rev Anticancer Ther. 2009 Apr;9(4):401-12
19374595
Diagn Mol Pathol. 2009 Sep;18(3):133-7
19704257
Clin Cancer Res. 2009 Jul 1;15(13):4493-8
19531624
Ann Pathol. 2010 Apr;30(2):85-93
20451063
Cancer. 2007 May 1;109(9):1836-44
17387741
J Mol Diagn. 2008 May;10(3):242-8
18403609
N Engl J Med. 2008 Mar 13;358(11):1160-74
18337605
Annu Rev Med. 2008;59:429-42
17716025
Diagn Mol Pathol. 2004 Dec;13(4):213-6
15538111
J Cancer Res Clin Oncol. 2005 Mar;131(3):199-203
15592685
J Clin Oncol. 2006 Nov 1;24(31):5034-42
17075123
J Clin Oncol. 2005 Nov 1;23(31):8081-92
16204011
Arch Pathol Lab Med. 2008 Oct;132(10):1635-47
18834223
BMC Cancer. 2009 Jan 07;9:6
19128465
Br J Cancer. 2010 May 25;102(11):1627-35
20461082
Nat Rev Cancer. 2007 Mar;7(3):169-81
17318210
J Clin Oncol. 2005 Apr 10;23(11):2513-20
15738541
Chest. 1997 Jun;111(6):1710-7
9187198
Cancer Res. 2004 Dec 1;64(23):8534-40
15574759
J Clin Oncol. 2005 Oct 1;23(28):6838-45
15998906
World J Gastrointest Oncol. 2010 Jan 15;2(1):5-8
21160810
Thyroid. 2009 Nov;19(11):1239-48
19888862
Thorax. 2006 Feb;61(2):140-5
16284218
N Engl J Med. 2008 Sep 25;359(13):1367-80
18815398
J Clin Oncol. 2004 Aug 15;22(16):3238-47
15310767
N Engl J Med. 2005 Jul 14;353(2):133-44
16014883
J Mol Diagn. 2008 Mar;10(2):160-8
18258923
J Thorac Oncol. 2007 Apr;2(4):327-43
17409807
Nat Rev Drug Discov. 2003 Dec;2(12):962-72
14654795
Br J Cancer. 2004 Jul 19;91(2):208-12
15187994
Pediatr Blood Cancer. 2009 Feb;52(2):209-14
19006223
J Cancer Res Clin Oncol. 2008 May;134(5):569-77
17932690
Hum Pathol. 2009 Mar;40(3):356-65
18976796
Eur J Surg Oncol. 2007 Oct;33(8):956-60
17374474
Exp Cell Res. 2003 Mar 10;284(1):31-53
12648464
J Clin Oncol. 2003 Oct 15;21(20):3798-807
12953099
J Natl Cancer Inst. 2005 May 4;97(9):643-55
15870435
Cancer Epidemiol Biomarkers Prev. 2010 Apr;19(4):1004-11
20332280
Br J Cancer. 2007 Mar 26;96(6):857-63
17325698